Clinical Pharmacokinetics

, Volume 29, Supplement 1, pp 1–9 | Cite as

Overview of the Pharmacokinetics of Fluvoxamine

  • Jaap van Harten


The pharmacokinetics of fluvoxamine, a selective serotonin reuptake inhibitor (SSRI) with antidepressant properties, are well established. After oral administration, the drug is almost completely absorbed from the gastrointestinal tract, and the extent of absorption is unaffected by the presence of food. Despite complete absorption, oral bioavailability in man is ≈ 50% on account of first-pass hepatic metabolism. Peak plasma fluvoxamine concentrations are reached 4 to 12 hours (enteric-coated tablets) or 2 to 8 hours (capsules, film-coated tablets) after administration. Steady-state plasma concentrations are achieved within 5 to 10 days after initiation of therapy and are 30 to 50% higher than those predicted from single dose data. Fluvoxamine displays nonlinear steady-state pharmacokinetics over the therapeutic dose range, with disproportionally higher plasma concentrations with higher dosages. Plasma fluvoxamine concentrations show no clear relationship with antidepressant response or severity of adverse effects.

Fluvoxamine undergoes extensive oxidative metabolism, most probably in the liver. Nine metabolites have been identified, none of which are known to be pharmacologically active. The specific cytochrome P450 (CYP) isoenzymes involved in the metabolism of fluvoxamine are unknown. CYP2D6, which is crucially involved in the metabolism of paroxetine and fluoxetine, appears to play a clinically insignificant role in the metabolism of fluvoxamine. The drug is excreted in the urine, predominantly as metabolites, with only negligible amounts (< 4%) of the parent compound.

Fluvoxamine shows a biphasic pattern of elimination with a mean terminal elimination half-life of 12 to 15 hours after a single oral dose; this is prolonged by 30 to 50% at steady-state. Plasma protein binding of fluvoxamine (77%) is low compared with that of other SSRIs.

Fluvoxamine pharmacokinetics are substantially unaltered by increased age or renal impairment. However, its elimination is prolonged in patients with hepatic cirrhosis. Fluvoxamine inhibits oxidative drug metabolising enzymes (particularly CYP1A2, and less potently and much less potently CYP3A4 and CYP2D6, respectively) and has the potential for clinically significant drug interactions. Drugs whose metabolic elimination is impaired by fluvoxamine include tricyclic antidepressants (tertiary, but not secondary, amines), alprazolam, bromazepam, diazepam, theophylline, propranolol, warfarin and, possibly, carbamazepine.


  1. 1.
    Benfield P, Ward A. Fluvoxamine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness. Drugs 1986; 32: 313–34PubMedCrossRefGoogle Scholar
  2. 2.
    Wilde MI, Plosker JL, Benfield P. Fluvoxamine. An updated review of its pharmacology, and therapeutic use in depressive illness. Drugs 1993; 46: 895–924PubMedCrossRefGoogle Scholar
  3. 3.
    Wagner W, Plekkenpol B, Gray TE, et al. Safety database of fluvoxamine: analysis and report. Pharmacopsychiat 1993; 26 Suppl.: 10–6CrossRefGoogle Scholar
  4. 4.
    Van Harten J. Clinical pharmacokinetics of selective serotonin re-uptake inhibitors. Clin Pharmacokinet 1993; 24: 203–20PubMedCrossRefGoogle Scholar
  5. 5.
    Van Harten J, Lönnebo A, Grahnén A. Pharmacokinetics of fluvoxamine after intravenous and oral administration. Neuropsychopharmacol 1994; 10 (3 Pt 2): 104SGoogle Scholar
  6. 6.
    De Bree H, Van der Schoot JB, Post LC. Fluvoxamine maleate: disposition in man. Eur J Drug Metab Pharmacokinet 1983; 8: 175–9CrossRefGoogle Scholar
  7. 7.
    Perucca E, Gatti G, Spina E. Clinical pharmacokinetics of fluvoxamine. Clin Pharmacokinet 1994; 27: 175–90PubMedCrossRefGoogle Scholar
  8. 8.
    Greb WH, Brett MA, Buscher G, et al. Absorption of paroxetine under various dietary conditions and following antacid intake. Acta Psychiatr Scand 1989; 80Suppl. 350: 99–101CrossRefGoogle Scholar
  9. 9.
    Van Harten J, Van Bemmel P, Dobrinska MR, et al. Bioavailability of fluvoxamine given with and without food. Biopharm Drug Disp 1991; 12: 571–76CrossRefGoogle Scholar
  10. 10.
    De Vries MH, Van Harten J, Van Bemmel P, et al. Pharmacokinetics of fluvoxamine maleate after increasing single oral doses in healthy subjects. Biopharm Drug Dispos 1993; 14: 291–6PubMedCrossRefGoogle Scholar
  11. 11.
    De Vries MH, Raghoebar M, Mathlener IS, et al. Single and multiple oral dose fluvoxamine kinetics in young and elderly subjects. Ther Drug Monit 1992; 14: 493–8PubMedCrossRefGoogle Scholar
  12. 12.
    Bouquet S, Vandel S, Bertschy G, et al. Pharmacokinetics of fluoxetine and fluvoxamine in depressed patients: personal results. Clin Neuropharmacol 1992; 15 (1 Suppl.): 82A–3APubMedCrossRefGoogle Scholar
  13. 13.
    Härtter S, Szegedi A, Wetzel H, et al. Differential interactions of fluvoxamine and paroxetine with the metabolism of tricyclic antidepressants. Pharmacopsychiatry 1993; 26: 156Google Scholar
  14. 14.
    Ciaassen V. Review of the animal pharmacology and pharmacokinetics of fluvoxamine. Brit J Clin Pharmacol 1983; 15 (3 Suppl): 349S–55SCrossRefGoogle Scholar
  15. 15.
    Overmars, H, Scherpenisse PM, Post LC. Fluvoxamine maleate: metabolism in man. Eur J Drug Metab Pharmacokinet 1983; 8: 269–80PubMedCrossRefGoogle Scholar
  16. 16.
    Sindrup SH, Brøsen K, Gram LF, et al. The relationship between paroxetine and the sparteine oxidation polymorphism. Clin Pharmacol Ther 1992; 51: 278–87PubMedCrossRefGoogle Scholar
  17. 17.
    Bergstrom RF, Lemberger L, Farid NA, et al. Clinical pharmacology and pharmacokinetics of fluoxetine: a review. Br J Psychiatry 1988; 153Suppl. 3: 47–50Google Scholar
  18. 18.
    Raghoebar M, Roseboom H. Kinetics of fluvoxamine in special populations [poster]. Symposium on Variability in Pharmacokinetics and Drug Response; 1988 Oct 3–5; GothenburgGoogle Scholar
  19. 19.
    Van Harten J, Duchiers J, Devissaguet J-P, et al. Pharmacokinetics of fluvoxamine maleate in patients with liver cirrhosis after single-dose oral administration. Clin Pharmacokinet 1993; 24: 177–82PubMedCrossRefGoogle Scholar
  20. 20.
    Goodnick PJ. Pharmacokinetic optimisation of therapy with newer antidepressants. Clin Pharmacokinet 1994; 27: 307–30PubMedCrossRefGoogle Scholar
  21. 21.
    Wright S, Dawling S, Ashford JJ. Excretion of fluvoxamine in breast milk. Brit J Clin Pharmacol 1991; 31: 209CrossRefGoogle Scholar
  22. 22.
    Kasper S, Dotsch M, Vieira A. Plasma levels of fluvoxamine and maprotiline and clinical response in major depression. Pharmacopsychiatry 1992; 25: 106Google Scholar
  23. 23.
    Kasper S, Dotsch M, Kick H, et al. Plasma concentrations of fluvoxamine and maprotiline in major depression: implications of therapeutic efficacy and side effects. Eur Neuropsychopharmacol 1993; 3: 13–21PubMedCrossRefGoogle Scholar
  24. 24.
    De Wilde JEM, Doogan DP. Fluvoxamine and chlorimipramine in endogenous depression. J Affect Disord 1982; 4: 249–59PubMedCrossRefGoogle Scholar
  25. 25.
    Brøsen K, Skielbo E, Rasmussen BB, et al. Fluvoxamine is a potent inhibitor of cytochrome P4501A2. Biochem Pharmacol 1993; 45: 1211–4PubMedCrossRefGoogle Scholar
  26. 26.
    Fleishaker JC, Hulst LK. A pharmacokinetic and pharmacodynamic evaluation of the combined administration of alprozolam and fluoxamine. Eur J Clin Pharmacol 1994; 46: 35–39PubMedCrossRefGoogle Scholar
  27. 27.
    Flockhart DA. Drug interactions and the cytochrome P450 system: the role of cytochrome P450 2C19. Clin Pharmacokinet 1995; 29Suppl. 1: 45–52PubMedCrossRefGoogle Scholar
  28. 28.
    Crewe HK, Lennard MS, Tucker GT, et al. The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes. Brit J Clin Pharmacol 1992; 34: 262–5CrossRefGoogle Scholar
  29. 29.
    Van Harten J, Stevens LA, Raghoebar M, et al. Fluvoxamine does not interact with alcohol or potentiate alcohol-related impairment of cognitive function. Clin Pharmacol Ther 1992; 52: 427–35PubMedCrossRefGoogle Scholar
  30. 30.
    Weilburg JB, Rosenbaum JF, Meltzer-Brody S, et al. Tricyclic augmentation of fluoxetine. Ann Clin Psychiatry 1991; 3: 209–14CrossRefGoogle Scholar
  31. 31.
    Wetzel H, Härtter S, Szegedi A, et al. Fluvoxamine comedication to tricyclic antidepressants: metabolic interactions, clinical efficiency and side effects. Pharmacopsychiatry 1993; 26: 211Google Scholar
  32. 32.
    Bertschy G, Vandel S, Vandel B, et al. Fluvoxamine-tricyclic antidepressant interaction. An accidental finding. Eur J Clin Pharmacol 1991; 40: 119–20PubMedCrossRefGoogle Scholar
  33. 33.
    Härtter S, Wetzel H, Hammes E, et al. Inhibition of antidepressant demethylation and hydroxylation by fluvoxamine in depressed patients. Psychopharmacol 1993; 110: 303–8Google Scholar
  34. 34.
    Spina E, Pollicino AM, Avenoso A, et al. Effect of fluvoxamine on the pharmacokinetics of imipramine and desipramine in healthy subjects. Ther Drug Monit 1993; 15: 243–6PubMedCrossRefGoogle Scholar
  35. 35.
    Spina E, Pollicino AM, Avenoso A, et al. Fluvoxamine-induced alterations in plasma concentrations of imipramine and desipramine in depressed patients. Int J Clin Pharmacol Res 1993; 13: 167–71PubMedGoogle Scholar
  36. 36.
    Seifritz E, Holsboer-Trachsler E, Hemmeter U, et al. Increased trimipramine plasma levels during fluvoxamine comedication. Pharmacopsychiatry 1993; 26: 195CrossRefGoogle Scholar
  37. 37.
    Skjelbo E, Brøsen K. Inhibitors of imipramine metabolism by human liver microsomes. Brit J Clin Pharmacol. 1992; 34: 256–61CrossRefGoogle Scholar
  38. 38.
    Spina E, Campo GM, Avenoso A, et al. Interaction between fluvoxamine and imipramine/desipramine in four patients. Ther Drug Monit 1992; 14: 194–6PubMedCrossRefGoogle Scholar
  39. 39.
    Ochs HR, Greenblatt DJ, Verburg-Ochs B, et al. Chronic treatment with fluvoxamine, clovoxamine, and placebo: interaction with digoxin and effects on sleep and alertness. J Clin Pharmacol 1989; 29: 91–5PubMedGoogle Scholar
  40. 40.
    Perucca E, Gatti G, Cipolla G, et al. Inhibition of diazepam metabolism by fluvoxamine: a pharmacokinetic study in normal volunteers. Clin Pharmacol Ther 1994; 56: 471–6PubMedCrossRefGoogle Scholar
  41. 41.
    Van Harten J, Holland RL, Wesnes K. Influence of multipledose administration of fluvoxamine on the pharmacokinetics of the benzodiazepines bromazepam and lorazepam: a randomized, cross-over study. Eur Neuropsychopharmacol 1992; 2: 381CrossRefGoogle Scholar
  42. 42.
    Hendrickx B, Floris M. A controlled pilot study of the combination of fluvoxamine and lithium. Curr Ther Res 1991; 49: 106–10Google Scholar
  43. 43.
    Evans M, Marwick P. Fluvoxamine and lithium: an unusual interaction. Brit J Psychiatry 1990; 156: 286CrossRefGoogle Scholar
  44. 44.
    Stimmel GL, Skowron DM, Chameides WA. Focus on fluvoxamine: a serotonin reuptake inhibitor for major and obsessive compulsive disorder. Hospital Formulary 1991; 26: 635–43Google Scholar
  45. 45.
    Diot P, Jonville AP, Gerard F, et al. Possible interaction entre theophylline et fluvoxamine. Therapie 1991; 46: 170–1PubMedGoogle Scholar
  46. 46.
    Sperber AD. Toxic interaction between fluvoxamine and sustained release theophylline in an 11-year-old boy. Drug Saf 1991; 6: 460–2PubMedCrossRefGoogle Scholar
  47. 47.
    Jerling M, Lindström L, Bondesson U, et al. Fluvoxamine inhibition and carbamazepine induction of the metabolism of clozapine: evidence from a therapeutic drug monitoring service. Ther Drug Monit 1994; 16: 368–74PubMedCrossRefGoogle Scholar
  48. 48.
    Fritze J, Unsorg B, Lanczik M. Interaction between carbamazepine and fluvoxamine. Acta Psychiatr Scand 1991; 84: 583–4PubMedCrossRefGoogle Scholar
  49. 49.
    Spina E, Avenoso A, Pollicino AM, et al. Carbamazepine coadministration with fluoxetine or fluvoxamine. Ther Drug Monit 1993; 15: 247–50PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 1995

Authors and Affiliations

  • Jaap van Harten
    • 1
  1. 1.Department of Clinical PharmacologySolvay Duphar BV, Pharmaceutical DivisionWeespThe Netherlands

Personalised recommendations